期刊文献+

Prognostic Potential of B - type Natriuetic Peptide and Quality of Life in Patients with Chronic Heart Failure

Prognostic Potential of B - type Natriuetic Peptide and Quality of Life in Patients with Chronic Heart Failure
下载PDF
导出
摘要 Objectives To study wheth- er change of BNP levels reflect the change of cardiac function and to investigate the short - term prognostic potential of BNP and QOL in patients with CHF. Methods 96 consecutive patients admittedwith CHF between September 2002 and January 2003 were stud- ied , upon entry the study, BNP levels were measured, Patients administered the disease - specificquality of life questionnaire Minnesota living with heart failure questionnaire (LiHFe) within 1 day. BNP levels and administering LiHFe were repeated three months later. Results BNP levels were increased proportional to the severity of cardiac function. Physical domain and total score of LiHFe were significantly correlated to the severity of CHF ( p < 0. 05 ). BNP levels were de- creased in improving group(p =0. 032) . In deteriora- ting group BNP levels increased (P = 0. 043 ) . Kaplan - meier analysis according to BNP level cutoff point 150 ng/1, the life curve of higher BNP level group was significantly lower than the lower group ( p = 0. 001 ) . In univariate logistic regression, NYHA class, BNP, LVEF, LVEDD, heart size, total score of LiHFe, phys- ical domain of LiHFe and the emotional domain of LiH- Fe were all significant prognostic factors of CHF ( p < 0. 05 for all). While in multiple regression, only BNP level( p = 0. 036) and the emotional domain of LiHFe ( p = 0. 025 ) were independent prognostic factors. Conclusions Change of BNP reflects the treatment efficacy of CHF. BNP and QOL are the two major short - time prognostic factors of the chronic heart failure patients. Objectives To study wheth- er change of BNP levels reflect the change of cardiac function and to investigate the short - term prognostic potential of BNP and QOL in patients with CHF. Methods 96 consecutive patients admittedwith CHF between September 2002 and January 2003 were stud- ied , upon entry the study, BNP levels were measured, Patients administered the disease - specificquality of life questionnaire Minnesota living with heart failure questionnaire (LiHFe) within 1 day. BNP levels and administering LiHFe were repeated three months later. Results BNP levels were increased proportional to the severity of cardiac function. Physical domain and total score of LiHFe were significantly correlated to the severity of CHF ( p < 0. 05 ). BNP levels were de- creased in improving group(p =0. 032) . In deteriora- ting group BNP levels increased (P = 0. 043 ) . Kaplan - meier analysis according to BNP level cutoff point 150 ng/1, the life curve of higher BNP level group was significantly lower than the lower group ( p = 0. 001 ) . In univariate logistic regression, NYHA class, BNP, LVEF, LVEDD, heart size, total score of LiHFe, phys- ical domain of LiHFe and the emotional domain of LiH- Fe were all significant prognostic factors of CHF ( p < 0. 05 for all). While in multiple regression, only BNP level( p = 0. 036) and the emotional domain of LiHFe ( p = 0. 025 ) were independent prognostic factors. Conclusions Change of BNP reflects the treatment efficacy of CHF. BNP and QOL are the two major short - time prognostic factors of the chronic heart failure patients.
出处 《South China Journal of Cardiology》 CAS 2004年第2期80-86,102,共8页 岭南心血管病杂志(英文版)
关键词 Chronic heart failure B - TYPE NATRIURETIC PEPTIDE (BNP) Prognosis Quality of life(QOL) Chronic heart failure B - type natriuretic peptide ( BNP) Prognosis Quality of life (QOL)
  • 相关文献

参考文献22

  • 1[1]Zhu SJ. Prophylaxis and therapy of chronic heart failure.Chinese J of Cardiovascular Disease 2002; 30:575 - 576.
  • 2[2]Krumholz HM, Chen Y, Wang Y, et al. Predictors of readmission among elderly survivors of admission with heart failure. Am Heart J 2000; 139:72 -77.
  • 3[3]Gullestad L, et al. Effect of metoprolol on cytokine levels in chronic heart failure - A Substudy in the Metoprolol Controlled- released Randomized Intervention Trialin Heart Failure( MERIF - HF). Am Heart J 2001; 141:418 -422.
  • 4[4]Krum - A, et al. New and emerging pharmacological strategies in the management of chronic heart failure. Curr - Opin- Pharmacol 2001; 1 (2) :126 - 133.
  • 5[5]Stein BC, Levin RL. Natriuretic peptides: physiology,therapeutic potential, and risk stratification ischemic heart disease. Am Heart J 1998; 135:914-923.
  • 6[6]Tsutamoto T, Wada A, Maeda K, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure. Circulation 1997; 96:509 -516.
  • 7[7]Sudoh T, Kangawa K, Minemino N, et al. A new natriuretic peptide in porcine brain. Nature 1988; 332:78 -81.
  • 8[8]Dhingra H, Roong Scritong C, Kurtzman NA et al. BNP:role in cardiovascular and volume homeostasis. Senin-Nephrol 2002; 22:423 - 437.
  • 9[9]Huang WS, Lee MS, Perng HW, et al. Circulating BNP values in healthy men before and after exercise. Metabolism2002; 51:1423 - 1426.
  • 10[10]Cowie Martin R, Mendez Gustavo F, et al. BNP and congestive heart failure. Prog Cardiovasc Disn 2002; 44(4):293 - 321

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部